This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Pragma Therapeutics, Calliditas Therapeutics Suisse Sa. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: The Innovations of Sylvain Celanire: A Visionary in Pharmaceutical Chemistry
Introduction: Sylvain Celanire is a prominent inventor based in Reignier-Esery, France, recognized for his significant contributions to pharmaceutical chemistry. With a total of three patents to his name, his work focuses on developing innovative compounds that target specific medical conditions, paving the way for advancements in therapeutic treatments.
Latest Patents: Celanire's most recent inventions include notable patents that highlight his expertise in modulating critical biochemical pathways. One of his latest patents is titled "Heterocyclic compounds as modulators of mGluR7." This invention pertains to novel heterocyclic compounds that serve as modulators of the metabotropic glutamate receptor subtype 7 (mGluR7). The patent outlines not only the compounds but also their pharmaceutical compositions and potential applications in treating disorders associated with glutamate dysfunction. Additionally, he has developed "Compounds as NADPH oxidase inhibitors," which refers to new compounds and pharmaceutical compositions aimed at treating conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
Career Highlights: Sylvain Celanire has established a remarkable career through his groundbreaking research and innovation in the pharmaceutical field. He has worked with renowned companies like Pragma Therapeutics and Calliditas Therapeutics, where he contributed valuable insights and expertise in drug development and research.
Collaborations: Throughout his career, Celanire has collaborated with several talented individuals in the research community. Notable colleagues include Guillaume Duvey and Peter Machin, with whom he has worked on various projects and patents, further enhancing the quality and impact of his inventions.
Conclusion: Sylvain Celanire's inventive spirit and dedication to advancing pharmaceutical chemistry have led to significant innovations in the treatment of complex medical conditions. With his impressive portfolio of patents and collaborations, he continues to be a driving force in the field, offering hope for future therapeutic breakthroughs.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile